After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Earlier, Yahoo Finance discussed this stock as it revealed Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
Erasca Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. The current market capitalization of Erasca Inc is $362.62M. A total of 3.06 million shares were traded on the day, compared to an average of 1.21M shares.
Insider Activity
Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, ERAS has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 4 BUYs and 0 SELLs from insiders. Insiders purchased 1,220,000 shares during that period but sold 0.
In the most recent transaction, Lim Jonathan E bought 278,150 shares of ERAS for 1.72 per share on Dec 06. After the transaction, the Chairman & CEO now owns 12,899,360 company shares. In a previous transaction on Dec 06, Start Valerie Denise Harding bought 10,000 shares at 1.85 per share. ERAS shares that Director owns now total 20,000.
Among the insiders who bought shares, Lim Jonathan E acquired of 721,850 shares on Dec 05 at a per-share price of $1.69. This resulted in the Chairman & CEO holding 12,899,360 shares of ERAS after the transaction. In another insider transaction, Casdin Alexander W. bought 30,000 shares at $1.66 per share on Dec 04. Company shares held by the Director now total 493,974.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for ERAS in the last 3 months, the mean price target is $6.83 with high estimates of $8.00 and low estimates of $6.00. In terms of 52-week highs and lows, ERAS has a high of $3.88 and a low of $1.51.
As of this writing, ERAS has an earnings estimate of -$0.21 per share for the current quarter. EPS was calculated based on a consensus of 6 estimates, with a high estimate of -$0.18 per share and a lower estimate of -$0.23. The company reported an EPS of -$0.21 in the last quarter, which was 12.50% higher than expectations of -$0.24.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. ERAS’s latest balance sheet shows that the firm has $414.48M in Cash & Short Term Investments as of fiscal 2021. There were $18.79M in debt and $26.22M in liabilities at the time. Its Book Value Per Share was $2.25, while its Total Shareholder’s Equity was $456.53M.
Analysts Opinion
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ERAS is Buy with a score of 4.67.
